Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 340

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 340
---
4,620 Net earnings— — — — 1,316 1,316 Unrealized gain on marketable securities, net of tax— — — 2,617 — 2,617 Balance, December 31, 202354,723,356 55 439,493 (593)482,561 921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 27,755 — — 27,755 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld1,019,739 1 12,192 — — 12,193 Net earnings— — — — 73,865 73,865 Unrealized gain on marketable securities, net of tax— — — 404 — 404 Balance, December 31, 202455,743,095 $56 $479,440 $(189)$556,426 $1,035,733 

See accompanying notes.

95

Supernus Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31, 202420232022Cash flows from operating activities   Net earnings$73,865 $1,316 $60,711 Adjustments to reconcile net earnings to net cash provided by operating activities:Depreciation and amortization80,414 84,859 85,543 Other income from Navitor (see Note 4)— — (12,888)Intangible asset impairment charges— 20,189 — Amortization of deferred financing costs and debt discount— 532 2,112 Realized gains from sales of marketable securities(9)— (14)Amortization of premium/discount on marketable securities1,823 (122)3,233 Change in fair value of contingent consideration(6,110)(1,517)(510)Share-based compensation expense27,755 26,759 17,568 Deferred income tax benefit(20,136)(25,714)(26,324)Inventory valuation write-down8,876 8,023 10,442 Other noncash adjustments, net7,525 5,897 1,196 Changes in operating assets and liabilities:Accounts receivable2,078 18